This site is intended for healthcare professionals

account_circleSign in
Go to /sign-in page

You can view 5 more pages before signing in

Methotrexate in rheumatoid arthritis

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Response to treatment cannot be expected before 2 months and may not occur until after 6 months treatment.

  • increasingly popular drug for this condition in the USA
  • once weekly dose
  • long term tolerability is better than that of gold, sulphasalazine, or penicillamine.
  • disease suppression starts earlier that with other slow-acting antirheumatics and patients are less likely to stop treatment
  • toxic effects include:
    • pneumonitis in 3% of patients
    • bone marrow suppression in approximately 3%
    • opportunistic infections
    • accelerated nodulosis of the hands
    • cirrhosis and liver failure - very rarely
  • overall side-effects are less common and can be minimised by folic acid supplementation

Reference:

  1. Porter DR. Medical management of rheumatoid arthritis. BMJ 1993; 307:425-428.
  2. Drug and Therapeutics Bulletin (1995). Methotrexate and rheumatoid arthritis. 33(3):17-19.
  3. Current Problems in Pharmacovigilance 2000; 26: 10.

Related pages

Create an account to add page annotations

Create a free account

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page